About Cadelius
Vitamin D and calcium supplement in addition to specific osteoporosis treatment of patients who are at risk of vitamin D or calcium deficiency, when a dietary supplement as large as 600 mg/day of calcium and 1000 IU/day of Vitamin D3 is supposed to be adequate.
Prevention and treatment of calcium and vitamin D deficiency in the elderly.
Cadelius Tolerability
Like all medicines, this medicine can cause side effects, although not everybody gets them. You should advise your patient to stop taking Cadelius if they experience symptoms of serious allergic reactions, such as:
- swollen face, lips, tongue or throat
- difficult to swallow
- hives and difficulty breathing
Adverse reactions observed included:
Uncommon (may affect up to 1 in 100 people): hypercalcaemia (increased levels of serum calcium) and/or hypercalciuria (increased levels of urine calcium).
Rare (may affect up to 1 in 1,000 people): constipation, flatulence, nausea, abdominal pain, diarrhoea, pruritus, rash and urticaria.
Not known (frequency cannot be estimated from the available data): serious allergic reactions.
Other special population: Patients with renal impairment could have a potential risk of hyperphosphatemia, nephrolithiasis and nephrocalcinosis.
Reporting of side effects: Adverse events / side effects should be reported. This includes any possible side effects not listed in this leaflet.
See the Cadelius Summary of Characteristics for Further Information
1. Cadelius Summary of Product Characteristics, available on medicines.ie
IE-CAD-81(13) DOP: October 2025
Adverse events should be reported. Reporting forms and information are available from HPRA Pharmacovigilance on the HPRA website www.hpra.ie.
Adverse events should also be reported to Consilient Health at drugsafety@consilienthealth.com or 012057766.
The information on this website is intended for Healthcare Professionals who practice in the Republic of Ireland only.